CN114846009A - 具有khk抑制作用的化合物 - Google Patents

具有khk抑制作用的化合物 Download PDF

Info

Publication number
CN114846009A
CN114846009A CN202080089222.9A CN202080089222A CN114846009A CN 114846009 A CN114846009 A CN 114846009A CN 202080089222 A CN202080089222 A CN 202080089222A CN 114846009 A CN114846009 A CN 114846009A
Authority
CN
China
Prior art keywords
compound
reaction
added
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080089222.9A
Other languages
English (en)
Other versions
CN114846009B (zh
Inventor
潘志祥
贺海鹰
江志赶
夏建华
张蕾
张臣
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Publication of CN114846009A publication Critical patent/CN114846009A/zh
Application granted granted Critical
Publication of CN114846009B publication Critical patent/CN114846009B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了一类具有KHK抑制作用的化合物或其药学上可接受的盐，及其在制备KHK激酶异常表达相关疾病的药物中的应用。具体公开了式(III)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080089222.9A 2019-12-24 2020-12-24 具有khk抑制作用的化合物 Active CN114846009B (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
CN2019113473646 2019-12-24
CN201911347364 2019-12-24
CN2020100426851 2020-01-15
CN202010042685 2020-01-15
CN2020102378941 2020-03-30
CN202010237894 2020-03-30
CN2020103659815 2020-04-30
CN202010365981 2020-04-30
CN2020104632222 2020-05-27
CN202010463222 2020-05-27
CN2020108133204 2020-08-13
CN202010813320 2020-08-13
CN202011051594 2020-09-29
CN2020110515940 2020-09-29
CN2020114903057 2020-12-16
CN202011490305 2020-12-16
PCT/CN2020/139012 WO2021129737A1 (zh) 2019-12-24 2020-12-24 具有khk抑制作用的化合物

Publications (2)

Publication Number Publication Date
CN114846009A true CN114846009A (zh) 2022-08-02
CN114846009B CN114846009B (zh) 2023-12-12

Family

ID=76575682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080089222.9A Active CN114846009B (zh) 2019-12-24 2020-12-24 具有khk抑制作用的化合物

Country Status (7)

Country Link
US (1) US20230138901A1 (zh)
EP (1) EP4083034A4 (zh)
JP (1) JP7403661B2 (zh)
KR (1) KR20220127839A (zh)
CN (1) CN114846009B (zh)
TW (1) TWI764467B (zh)
WO (1) WO2021129737A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022262841A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种螺环化合物的盐型、晶型及其制备方法
WO2023121378A1 (ko) * 2021-12-24 2023-06-29 주식회사 엘지화학 (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물
WO2023151473A1 (zh) * 2022-02-09 2023-08-17 上海研健新药研发有限公司 一种khk抑制剂，其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939283A (zh) * 2010-04-22 2013-02-20 詹森药业有限公司 可用作己酮糖激酶抑制剂的吲唑化合物
US20130195886A1 (en) * 2011-11-27 2013-08-01 The Regents Of The University Of Colorado, A Body Corporate Methods for Fructanase and Fructokinase Inhibition
CN107001377A (zh) * 2014-12-08 2017-08-01 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5‑a]嘧啶衍生物
CN107406462A (zh) * 2015-03-09 2017-11-28 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN113412260A (zh) * 2019-01-29 2021-09-17 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
WO2021215765A1 (ko) * 2020-04-20 2021-10-28 주식회사 엘지화학 3-아자바이사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939283A (zh) * 2010-04-22 2013-02-20 詹森药业有限公司 可用作己酮糖激酶抑制剂的吲唑化合物
US20130195886A1 (en) * 2011-11-27 2013-08-01 The Regents Of The University Of Colorado, A Body Corporate Methods for Fructanase and Fructokinase Inhibition
CN107001377A (zh) * 2014-12-08 2017-08-01 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5‑a]嘧啶衍生物
CN107406462A (zh) * 2015-03-09 2017-11-28 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN113412260A (zh) * 2019-01-29 2021-09-17 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途

Also Published As

Publication number Publication date
EP4083034A1 (en) 2022-11-02
KR20220127839A (ko) 2022-09-20
US20230138901A1 (en) 2023-05-04
TW202128711A (zh) 2021-08-01
CN114846009B (zh) 2023-12-12
JP2023509001A (ja) 2023-03-06
WO2021129737A1 (zh) 2021-07-01
EP4083034A4 (en) 2023-12-06
TWI764467B (zh) 2022-05-11
JP7403661B2 (ja) 2023-12-22

Similar Documents

Publication Publication Date Title
CN112566637B (zh) Glp-1受体激动剂及其用途
JP6982054B2 (ja) Ｇｌｐ−１受容体アゴニストおよびその使用
JP7359974B2 (ja) 五員環ヘテロ芳香族イミダゾール系化合物及びその使用
CN114846009B (zh) 具有khk抑制作用的化合物
EP4166142A1 (en) Methyl-substituted benzobisoxazole compound and use thereof
CN108283000A (zh) γ-羟基丁酸的前药及其组合物和用途
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
CN108395443B (zh) 抑制程序性死亡受体配体1的环状化合物及其用途
WO2022166890A1 (zh) 取代的哒嗪苯酚类衍生物
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
CN112689638B (zh) 作为lsd1抑制剂的环丙胺类化合物及其应用
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
CN114634510A (zh) 咪唑并吡啶衍生物及其用途
JP2017514856A (ja) 糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ
WO2021129817A1 (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
WO2022237797A1 (zh) 烷基羧酸化合物及其应用
CN114286813A (zh) 取代的脲二氢乳清酸脱氢酶抑制剂
JP2021504330A (ja) ピリミジンスルファミド系誘導体、その製造方法およびその医薬における使用
JP7227427B2 (ja) Ｓｇｌｔ２／ｄｐｐ４阻害剤及びその使用
WO2023274418A1 (zh) 蛋白降解靶向嵌合体类化合物
CN114746089A (zh) 噻唑甲酰胺化合物及其用于治疗分枝杆菌感染的用途
CN114746421A (zh) 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN115702152A (zh) 内磺酰胺衍生物及其应用
TW202313595A (zh) 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)- 氧雜環丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羥基-2-(羥甲基)丙-2-胺鹽之固體形式
WO2024099404A1 (zh) 一种含氮螺环类化合物、药物组合物以及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant